{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092722","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.076568+00:00","generated_at":"2026-05-31T11:41:51.471362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biodesix Q2 revenue up 51% YoY to $17.9M; raises FY2024 guidance to $70-72M","bullets":["Q2 2024 revenue $17.9M, up 51% YoY; Lung Diagnostic $16.5M (+44%), Biopharma Services $1.4M (+228%).","Gross margin 78.4% vs 72.7% Q2 2023; net loss improved 19% to $10.8M; Adjusted EBITDA loss improved 38% to $5.6M.","Raises full-year 2024 revenue guidance to $70-72M from prior $65-68M.","Lung diagnostic test volume 13,900, up 42% YoY and 17% sequentially.","Cash $42.2M at June 30, 2024, including $55M from April stock offering."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092722","json":"https://secwatch.observer/filing/0000950170-24-092722.json","markdown":"https://secwatch.observer/filing/0000950170-24-092722.md","text":"https://secwatch.observer/filing/0000950170-24-092722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024092722/0000950170-24-092722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024092722/bdsx-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:41:51.471362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}